Divigel® gives women a convenient solution for relief of moderate to severe vasomotor symptoms due to menopause.

Divigel® is an estradiol gel that is invisible, odorless and non-sticky when dry. It delivers highly concentrated estradiol at 0.1%, so only a small amount of gel is applied once daily to the upper thigh.

Divigel® eliminated nearly 90% of vasomotor symptoms in 12 weeks with 1 mg/day.1

Once-Daily Application
  • Once-daily application for all-day, all-night estradiol coverage.
  • Divigel® offers 5 dosage strengths, including the lowest FDA-approved dose (0.25 mg/day) of transdermal estradiol gel or spray for effective relief of moderate to severe hot flashes.2
Premeasured Packets
  • Divigel® comes in small packets that are portable, discreet, and easy to use at home or away.
  • Divigel® samples include one week of therapy and a travel case.
  • Divigel® is appropriate for active lifestyles and in hot and humid conditions, where patch adhesion can be problematic.
Concentrated and Easy to Apply
  • Divigel® is a concentrated gel that is applied to a small area on the upper thigh.
  • Alternate between left and right thigh each day.
Invisible Gel
  • Divigel® is a gel that leaves no sticky residue.
  • It’s invisible and odorless when dry. Nobody knows you’re wearing it.
  • To reduce the risk of transmission, advise patients to wash hands, avoid skin contact until gel is completely dried, and cover the application site.
Divigel® Offers Savings
  • Divigel® has broad coverage on most insurance plans and is one of the lowest cost non-patch transdermal estrogen therapies.3
  • Eligible patients can enroll in the Patient Savings Program to save on 12 months of Divigel®.

Use estrogen-alone, or in combination with progestin, at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.

Effective Relief


Start Saving

1. Hedrick RE, Ackerman RT, Koltun WD, Halvorsen MB, Lambrecht LJ. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. Menopause. 2009;16(1):132-140.
2. Orange Book: Approved Drug Products with Therapeutic equivalence Evaluations. U.S. Food & Drug Administration. Accessed February 13, 2020. https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm
3. Data on file, Osmotica Pharmaceuticals 2019.

Alpharetta, GA 30005